Teicoplanin: Pharmacokinetic characteristics and antimicrobial spectrum;Caracteristicas farmacocineticas y espectro antimicrobiano de la teicoplanina

Medicina

Volumn 62, Issue SUPPL. 2, 2002, Pages 52-55

  Paganini, Hugo ^a,b   Marin, Marcelo ^a,b  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^b Fundacion Centro de Estudios Infectologicos   (Argentina)

Author keywords

Antibacterial spectrum; Pharmacological characteristics; Teicoplanin

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BONE INFECTION; CHILD; COAGULASE NEGATIVE STAPHYLOCOCCUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ENDOCARDITIS; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; INFECTIOUS ARTHRITIS; NEPHROTOXICITY; NONHUMAN; OUTPATIENT CARE; RASH; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; REVIEW;

ADULT; ANTI-BACTERIAL AGENTS; CHILD; HUMANS; TEICOPLANIN;

EID: 0036451203     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Lewis P, Garaud JJ, Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria. J Antimicrob Chemother 1988; 21: 61-7.
2. Glupczynski Y, Lagast H, Van der Auwera P et al. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria. Antimicrob Agents Chemother 1986; 29: 52-7.
3. Graninger W, Wenisch C, Wiesinger E y col. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14: 643-7.
4. Nagarajan R. Antibacterial activities and modes of action of vancomycin and related glycopeptides. Antimicrob Agents Chemother 1991; 35: 605-9.
5. Somma S, Gastaldo L, Corti A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. Sp. Antimicrob Agents Chemother 1984; 26: 917-23.
6. Reynolds PE, Structure, biochemistry and mechanism of action of glycoipeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989; 8: 943-50.
7. Johnson AP, Uttley AHC, Woodford N, George RC. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev 1990; 3: 280-91.
8. Gorzynski EA, Amsterdan D, Beam TR, Rolstein C. Comparative in vitro activities of telcoplanin, vancomycin, oxacillin and other antimicrobials agents against bacteremic isolates of Gram positive cocci. Antimicrob Agents Chemother 1989; 33: 2019-22.
9. Greenwood D. Microbiological properties of teicoplanin. J Antimicrob Chemother 1988; 21: 1-13.
10. Low DE, McGeer A, Poon R. Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evluation of susceptibility testing recommendations. Antimicrob Agents Chemother 1989; 33: 585-8.
11. Malabarba A, Strazzolini P, Depaoli A, Landi m, Berti M, Cavalleri B. Teicoplanin, antibiotics from Actinoplanes teichomyceticus nov. Sp. VI Chemical degradation: physico-cchemical and biological properties of acids hydrolysis products. A Antibiot 1984; 37: 988-99.
12. Morris AB, Brown RB, Sands M. Use of rifampicin in nonstaphylococcal, nonmycobacterial disease. Antimicrob Agents Chemother 1993; 37: 1-7.
13. Tuazon CU, Miller H. Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci. Antimicrob Agents Chemother 1984; 25: 411-2.
14. Watanakunakorn C, Bakie C. Synergism of vancomycin-gentamicin and vancomycin-streptomycin against enterococci. Antimicrob Agents Chemother 1973; 4: 120-4.
15. Watanakunakorn C, Tisone JC. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptibble and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1982; 22: 903-5.
16. McHenry MC, Gavan TL. Vancomycin. Pediatr Clin North Am 1983; 30: 31.
17. Fekety R. Vancomycin, teicoplanin and the streptogramins:quinupristin and dalfopristin. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pennsylvania: Churchill Livingstone, 2000, p 382-92.
18. Campoli Richards DM, Brogden RN, Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1990; 40: 449-86.
19. Smithers JA, Kulmala HK, Thompson GA, et al. Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers. Antimicrob Agents Chemother 1992; 36: 115-20.
20. García Sanchez JE, García Sanchez MI, García García y García Rodriguez JA. Glucopéptidos: vancomicina y teicoplanina. Rev Esp Quimioter 1993; 6: 275-82.
21. Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother 1996; 38: 507-21.
22. Brogden RN, Peters DH. Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 823-54.
23. Kinsey SE. Experience with teicoplanin in non-inpatient therapy in children with central line infections. Eur J Haematol 1998; 62: 11-4.
24. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-22.
25. LeFrock JL, Ristuccia AM, Ristuccia PA et al. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA. Eur J Surg 1992; 567: 9-13.
26. Rolston KV, Nguyen H, Amos G, Elting L, Fainstein V, Bodey GP. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 1994; 169: 350-5.
27. Chow AW, Jewesson PJ, Kureishi A, Phillips GL. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol Suppl 1993; 54: 18-24.
28. Schmit JL. Efficacy of teicoplanin for enterococcal infections: 63 cases and review. Clin Infect Dis 1992; 15: 302-6.
29. Al-Wali W, Baillod RA, Brumfitt W, Hamilton-Miller JMT. Teicoplanin in the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis: a comparative trial against vancomycin. Int J Antimicrob Agents. 1992; 1: 1-6.
30. de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36: 2192-6.
31. Periti P, Stringa G, Donati L, Mazzei T, Mini E, Novelli A. Teicoplanin-its role as systemic therapy of burn infections and as prophylaxis for orthopaedic surgery. Italian Study Groups for Antimicrobial Prophylaxis in Orthopaedic Surgery and Burns. Eur J Surg Suppl 1992: 3-8.